Wellbeing Subsidiary KGK Science Enters into Research Contract With Nova Mentis for Phase II A Clinical Trial
KGK to conduct Phase II clinical trial to test the efficacy of psilocybin on Fragile X syndrome VANCOUVER, British Columbia--(BUSINESS WIRE)--$KONEF #psychedelics--Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: